Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2019 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Changes to Senior Leadership Team

SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV)...
April 22, 2019 16:51 ET | Source: Assembly Biosciences, Inc.

Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development

SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
April 13, 2019 12:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019

- Favorable safety and tolerability profile- Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies- Selected for inclusion in “Best of ILC” presentation- Company to...
April 11, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019

Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a...
March 27, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019

SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
March 13, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
February 28, 2019 17:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results

SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
January 07, 2019 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus

SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
November 12, 2018 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a...
November 08, 2018 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update

ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate ...